single-injection once-monthly antibody delivered subcutaneously for the treatment of Alzheimer's disease that targets a key epitope at the N-terminus of amyloid beta (Aß) with high binding potency.

Personalized repetitive transcranial magnetic stimulation slowed cognitive and functional impairment in a phase 2 study of ...

Acumen, with a strong cash position of $258.9 million, is poised to sustain operations into 2027, boosting investor confidence in their innovative approach to targeting toxic amyloid beta oligomers in ...

The positive rate of amyloid beta protein, indicating the risk of Alzheimer's disease-causing substance accumulation, was ...

With our clinical program gaining momentum and sabirnetug’s unique selectivity for toxic amyloid beta oligomers, we are excited about the potential to offer a next-generation treatment for early ...

Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.

and they work by taking out amyloid beta from the brain. Amyloid is part of what causes Alzheimer's disease. Now, what we're ...

Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Leqembi’s sales continue to be underwhelming, according to analysts, who contend the companies’ Alzheimer’s disease therapy ...

But poor sleep is both a risk factor for and a symptom of Alzheimer's disease, making it tricky to tease apart cause and ...